After years of running trials for other drugmakers, TrialSpark is building its own pipeline

TrialSpark, one of several companies launched specifically to address the “mournful” cost of clinical development, now has $156 million more to work with — and with it, CEO Benjamine Liu has big plans to move into drug development.

Linhao Zhang

The biotech unicorn — valued...

Click to view original post